Evidence map›Paper›PMID 24216180›Full record

ArticleMolecular oncology2014

A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.

Kantima Leelahavanichkul, Panomwat Amornphimoltham, Alfredo A Molinolo, John R Basile, Sittichai Koontongkaew, J Silvio Gutkind

Open access · bronzeAbstract read
In one paragraph

Article in Molecular oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 130 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Targeting the MAPK Pathway in Cancer.International journal of molecular sciences · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Angiopoietin-like 4 is upregulated by amphiregulin and activates cell proliferation and migration through p38 kinase in head and neck squamous cell carcinoma.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Pathogens (Basel, Switzerland) · 2023
    Article
  19. Article
  20. Extracellular Vesicles Released from Macrophages Infected withInternational journal of molecular sciences · 2023
    Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kantima LeelahavanichkulOral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA; Faculty of Dentistry, Thammasat University, Pathumthani, Thailand.
Panomwat AmornphimolthamOral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
Alfredo A MolinoloOral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA.
John R BasileDepartment of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, MD, USA.
Sittichai KoontongkaewFaculty of Dentistry, Thammasat University, Pathumthani, Thailand.
J Silvio GutkindOral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, USA. Electronic address: sg39v@nih.gov.
National Institute of Dental and Craniofacial Research · USThammasat University · THUniversity of Maryland, Baltimore · US

Funding

Oral CarcinogenesisZIADE000558 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI GUTKIND, JORGE SILVIO · 2009 to 2015
$11.4M
ORAL CARCINOGENESISZ01DE000558 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI GUTKIND, J · 1992 to 2008
$3.6M
Intramural NIH HHS Z01 DE000558Intramural NIH HHS ZIA DE000558
6 · The paper itself

Abstract

We have recently gained a remarkable understanding of the mutational landscape of head and neck squamous cell carcinoma (HNSCC). However, the nature of the dysregulated signaling networks contributing to HNSCC progression is still poorly defined. Here, we have focused on the role of the family of mitogen activated kinases (MAPKs), extracellular regulated kinase (ERK), c-Jun terminal kinase (JNK) and p38 MAPK in HNSCC. Immunohistochemical analysis of a large collection of human HNSCC tissues revealed that the levels of the phosphorylated active form of ERK1/2 and JNK were elevated in less than 33% and 16% of the cases, respectively. Strikingly, however, high levels of active phospho-p38 were observed in most (79%) of hundreds of tissues analyzed. We explored the biological role of p38 in HNSCC cell lines using three independent approaches: treatment with a specific p38 inhibitor, SB203580; a retro-inhibition strategy consisting in the use of SB203580 combined with the expression of an inhibitor-insensitive mutant form of p38α; and short-hairpin RNAs (shRNAs) targeting p38α. We found that specific blockade of p38 signaling significantly inhibited the proliferation of HNSCC cells both in vitro and in vivo. Indeed, we observed that p38 inhibition in HNSCC cancer cells reduces cancer growth in tumor xenografts and a remarkable decrease in intratumoral blood and lymphatic vessels. We conclude that p38α functions as a positive regulator of HNSCC in the context of the tumor microenvironment, controlling cancer cell growth as well as tumor-induced angiogenesis and lymphangiogenesis.

Indexed as

LymphangiogenesisAnimalsCarcinoma, Squamous CellCell Line, TumorCell ProliferationCytokinesEnzyme ActivationFemaleHead and Neck NeoplasmsHumansMiceMice, NudeNeovascularization, Pathologicp38 Mitogen-Activated Protein KinasesSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentCytokinesp38 Mitogen-Activated Protein KinasesAngiogenesisHead and neck cancerJNKLymphangiogenesisMAPKp38 Inhibitorp38 MAPK

Identifiers

PMID24216180
PMCPMC3946852
OpenAlexW2037575576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.